Literature DB >> 6181154

A monoclonal antibody specific for the Thomsen-Friedenreich cryptic T antigen.

A F Rahman, B M Longenecker.   

Abstract

A monoclonal antibody (49H.24) is described that was made after immunization of BALB/c mice with human neuraminidase-treated erythrocytes (NE-RBC). 49H.24 is an IgM and reacts with NE-RBC but not untreated, normal human RBC. As little as 100 pg of antibody protein produced detectable direct agglutination of, or binding to, NE-RBC. The fine specificity of 49H.24 was determined by using a series of synthetic sugar haptens as inhibitors of agglutination or binding of 49H.24 to NE-RBC. Only synthetic T hapten (beta Gal(1 leads to 3)alpha GalNAc) produced complete inhibition of agglutination or binding, and no inhibition was produced by several other closely related haptens. Synthetic T hapten-coated silica beads (Synsorb) were used to affinity purify 49H.24. Affinity-purified antibody was radiolabeled with 125I and used in a sensitive competition assay to detect natural T antigen associated with cell membranes or in soluble form. The potential use of this or similar monoclonal antibodies as probes for an important human tumor marker is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181154

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Specificity studies of an antibody developed against a mucin-type glycoprotein.

Authors:  S Haavik; M Nilsen; T Thingstad; H Barsett; D V Renouf; E F Hounsell; J F Codington
Journal:  Glycoconj J       Date:  1999-03       Impact factor: 2.916

2.  Ricinus communis agglutinin II-reactive glycoproteins from the ascites of patients with hepatocellular carcinoma and their use in enzyme-linked immunosorbent assay.

Authors:  M Fukushima; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-04

3.  T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo.

Authors:  C M Henningsson; S Selvaraj; G D MacLean; M R Suresh; A A Noujaim; B M Longenecker
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 4.  Carbohydrates as antigenic determinants of glycoproteins.

Authors:  T Feizi; R A Childs
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

5.  Efficient generation in vitro, from human peripheral blood cells, of monoclonal Epstein-Barr virus transformants producing specific antibody to a variety of antigens without prior deliberate immunization.

Authors:  L Winger; C Winger; P Shastry; A Russell; M Longenecker
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

6.  In vivo localization of radioiodinated peanut lectin in a murine TA3/Ha mammary carcinoma model.

Authors:  A Shysh; S M Eu; A A Noujaim; M R Suresh; B M Longenecker
Journal:  Eur J Nucl Med       Date:  1985

7.  Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.

Authors:  S Adluri; F Helling; S Ogata; S Zhang; S H Itzkowitz; K O Lloyd; P O Livingston
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

8.  Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen.

Authors:  Jamie Heimburg-Molinaro; Adel Almogren; Susan Morey; Olga V Glinskii; Rene Roy; Gregory E Wilding; Richard P Cheng; Vladislav V Glinsky; Kate Rittenhouse-Olson
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

Review 9.  Organ specific metastasis with special reference to avian systems.

Authors:  M W Kieran; B M Longenecker
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule.

Authors:  W Dippold; A Steinborn; K H Meyer zum Büschenfelde
Journal:  Environ Health Perspect       Date:  1990-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.